Physician profile
Edward A Duda
NPI 1669469292
$14,365.82
in general payments reported to CMS, 2019-2025
70 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,444 · 2020: $3,550 · 2021: $16.04 · 2022: $86.91 · 2023: $1,215 · 2024: $2,893 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,137 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,136.76 |
| Education | $132.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,373.34 | 2019-2025 | |
| Genentech USA, INC. | $904.97 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Merck Sharp & Dohme LLC | $877.66 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $835.31 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $726.04 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Pfizer INC. | $688.74 | 2019-2025 | |
| Amgen INC. | $674.50 | 2019-2020 | |
| Janssen Biotech, INC. | $619.22 | 2019-2025 | Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $565.62 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Incyte Corporation | $449.10 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Abbvie INC. | $412.07 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $387.01 | 2019-2025 | |
| Genzyme Corporation | $329.81 | 2019-2024 | |
| Seagen INC. | $325.66 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $322.52 | 2020-2025 | Ojjaara, Jemperli |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Duda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.